Regulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest Down 18.1% in July

Regulus Therapeutics Inc. (NASDAQ:RGLS) was the target of a significant drop in short interest in July. As of July 15th, there was short interest totalling 4,340,000 shares, a drop of 18.1% from the June 30th total of 5,300,000 shares. Approximately 8.2% of the company’s stock are sold short. Based on an average daily trading volume, of 817,600 shares, the days-to-cover ratio is currently 5.3 days.

Institutional Investors Weigh In On Regulus Therapeutics

Several hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp acquired a new stake in shares of Regulus Therapeutics in the second quarter valued at approximately $352,000. Opaleye Management Inc. acquired a new stake in Regulus Therapeutics during the first quarter worth approximately $490,000. RA Capital Management L.P. bought a new stake in shares of Regulus Therapeutics during the first quarter worth approximately $18,000,000. NEA Management Company LLC bought a new position in shares of Regulus Therapeutics during the first quarter worth approximately $18,627,000. Finally, Vanguard Group Inc. lifted its holdings in Regulus Therapeutics by 158.4% during the 1st quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after purchasing an additional 453,784 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on RGLS shares. Canaccord Genuity Group lifted their target price on Regulus Therapeutics from $11.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. StockNews.com began coverage on shares of Regulus Therapeutics in a report on Tuesday, April 16th. They set a “sell” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research note on Tuesday, July 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $11.75.

Regulus Therapeutics Trading Up 2.8 %

Shares of Regulus Therapeutics stock traded up $0.05 on Monday, reaching $1.83. 635,519 shares of the company were exchanged, compared to its average volume of 1,733,447. Regulus Therapeutics has a one year low of $1.08 and a one year high of $3.79. The company has a 50-day moving average of $2.02 and a 200 day moving average of $1.98.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.14). Equities research analysts predict that Regulus Therapeutics will post -0.59 earnings per share for the current fiscal year.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.